Abstract: OBJECTIVE To evaluate the improvement in the efficiency and safety of Compound Kushen injection in the treatment of non-small cell lung cancer on the basis of pemetrexed and carboplatin. METHODS The 80 patients with non-small cell lung cancer were treated from January 2016 to September 2017. They were considered as study objects and the clinical data were analyzed retrospectively. They were divided into observation group (n=42) and control group (n=38). The patients were treated with Compound Kushen injection, pemetrexed and carboplatin in the observation group, while the patients were treated with pemetrexed and carboplatin in the control group. The treatment effects were observed and compared. RESULTS Compared with control group after treatment, in the observation group, the improvement about quality of life was significantly better (P<0.05); the CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were significantly higher (P<0.05), while the CD8⁺ was significantly lower (P<0.05); the levels of inflammatory indexes (IL-6, IL-10, TNF-α) were better (P<0.05); the effective rate and disease control rate were significantly higher (P<0.05); besides, the progression free survival and overall survival in the observation group were significantly higher (P<0.05); the adverse reaction of patients was significantly lower (P<0.05). CONCLUSION Compound Kushen injection, pemetrexed and carboplatin used in the treatment process of non-small cell lung cancer can effectively improve quality of life and immune function, reduce the level of inflammation indexes. The therapeutic regimen is safe and effective.